These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16130017)

  • 1. Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
    Whang PG; Gamradt SC; Gates JJ; Lieberman JR
    Prostate Cancer Prostatic Dis; 2005; 8(4):327-34. PubMed ID: 16130017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
    Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
    Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
    Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
    Goktas S; Baran Y; Ural AU; Yazici S; Aydur E; Basal S; Avcu F; Pekel A; Dirican B; Beyzadeoglu M
    Urology; 2010 Apr; 75(4):793-8. PubMed ID: 19800672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib as a potential treatment for prostate cancer.
    Papandreou CN; Logothetis CJ
    Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.
    Valentiner U; Haane C; Nehmann N; Schumacher U
    Anticancer Res; 2009 Apr; 29(4):1219-25. PubMed ID: 19414367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A
    Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
    Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts.
    Labussiere M; Pinel S; Delfortrie S; Plenat F; Chastagner P
    Oncol Rep; 2008 Nov; 20(5):1283-7. PubMed ID: 18949434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
    Shi WY; Wang L; Xiao D; Yao Y; Yang F; Jiang XX; Leboeuf C; Janin A; Chen SJ; Zhao WL
    Ann Hematol; 2011 Jan; 90(1):53-8. PubMed ID: 20617436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL; Lin JK
    Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proteasome: a worthwhile target for the treatment of solid tumours?
    Milano A; Iaffaioli RV; Caponigro F
    Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
    Bersani F; Taulli R; Accornero P; Morotti A; Miretti S; Crepaldi T; Ponzetto C
    Eur J Cancer; 2008 Apr; 44(6):876-84. PubMed ID: 18342500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.